Evidence map›Paper›PMID 34372597›Full record

ReviewViruses2021

Understanding Antibody Responses in Early Life: Baby Steps towards Developing an Effective Influenza Vaccine.

Elene A Clemens, Martha A Alexander-Miller

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. State of pneumococcal vaccine immunity.Human vaccines & immunotherapeutics · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Elene A ClemensDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA.ORCID 0000-0002-1943-8147
Martha A Alexander-MillerDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA.ORCID 0000-0003-3455-0716
Wake Forest University · US

Funding

Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Development of vaccine approaches to elicit broadly protective influenza-specific immune responses in infantsR01AI146059 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ALEXANDER-MILLER, MARTHA ANN · 2020 to 2024
$3.0M
Vaccination strategies to overcome immune deficiencies in neonatesR01AI098339 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ALEXANDER-MILLER, MARTHA ANN · 2012 to 2015
$2.3M
NCATS NIH HHS UL1 TR001420NIH HHS R01AI098339NIH HHS R01AI146059
6 · The paper itself

Abstract

The immune system of young infants is both quantitatively and qualitatively distinct from that of adults, with diminished responsiveness leaving these individuals vulnerable to infection. Because of this, young infants suffer increased morbidity and mortality from respiratory pathogens such as influenza viruses. The impaired generation of robust and persistent antibody responses in these individuals makes overcoming this increased vulnerability through vaccination challenging. Because of this, an effective vaccine against influenza viruses in infants under 6 months is not available. Furthermore, vaccination against influenza viruses is challenging even in adults due to the high antigenic variability across viral strains, allowing immune evasion even after induction of robust immune responses. This has led to substantial interest in understanding how specific antibody responses are formed to variable and conserved components of influenza viruses, as immune responses tend to strongly favor recognition of variable epitopes. Elicitation of broadly protective antibody in young infants, therefore, requires that both the unique characteristics of young infant immunity as well as the antibody immunodominance present among epitopes be effectively addressed. Here, we review our current understanding of the antibody response in newborns and young infants and discuss recent developments in vaccination strategies that can modulate both magnitude and epitope specificity of IAV-specific antibody.

Indexed as

Antibody FormationAdultAge FactorsAntibodies, ViralAntigenic VariationB-LymphocytesEpitopesHumansInfantInfant, NewbornInfluenza, HumanInfluenza VaccinesOrthomyxoviridaeAntibodies, ViralEpitopesInfluenza VaccinesantibodyB cellinfluenza virusnewbornTfhvaccine

Identifiers

PMID34372597
PMCPMC8310046
OpenAlexW3185065023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.